Notice of Allowability	Application No.	Applicant(s)	
	10/009,945	THOMSEN ET AL.	
	Examiner	Art Unit	
	Hope A. Robinson	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *10/30/07*.

2. ☒ The allowed claim(s) is/are *69-72,75,78,81-91,102 and 103*.

3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
   a) ☒ All b) ☐ Some* c) ☐ None of the:
      1. ☒ Certified copies of the priority documents have been received.
      2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
      3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
      1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
   (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
7. ☐ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

HOPE ROBINSON
PRIMARY EXAMINER

Hope A. Robinson
Primary Examiner
Art Unit: 1652

12/8/07

Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.-68. (Canceled)

69. (Currently amended) A method of screening for a modulator of Smurf activity which comprises detecting modulation of Smurf activity in the presence of a test compound relative to Smurf activity in the absence of the test compound, wherein the Smurf activity detected is the activity of a Smurf comprising a WW domain and a HECT domain, wherein the Smurf ~~has an amino acid sequence similarity of greater than 90% with~~ comprises the amino acid sequence depicted in SEQ ID NO:2, and wherein the Smurf activity is ubiquitination of a Smad polypeptide, ubiquitination of a TGFβ receptor or interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.

70. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell.

71. (Previously presented) The method according to claim 69, wherein the Smurf activity is interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.

72. (Previously presented) The method according to claim 71, wherein the test compound is screened for the ability to inhibit the interaction.

73. (Canceled)

74. (Canceled)

75. (Previously presented) The method according to claim 69, wherein the Smurf activity detected is the activity of a Smurf comprising the amino acid sequence depicted in SEQ ID NO:2.

76. (Canceled)

77. (Canceled)

78. (Previously presented) A method of screening for a modulator of Smurf activity which comprises detecting modulation of Smurf activity in the presence of a test compound relative to Smurf activity in the absence of the test compound, wherein the Smurf activity detected is activity of a human Smurf comprising the amino acid sequence depicted in SEQ ID NO:4, and wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell, interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide, or ubiquitination of a TGFβ receptor.

79. (Canceled)

80. (Canceled)

81. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a Smad polypeptide.

82. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell.

83. (Previously presented) The method according to claim 78, wherein the Smurf activity is interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.

84. (Previously presented) The method according to claim 83, wherein the test compound is screened for the ability to inhibit the interaction.

85. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a TGFβ receptor.

86. (Previously presented) The method according to claim 78, wherein the screening assay is conducted *in vitro.*

87. (Previously presented) The method according to claim 78, wherein the screening assay is conducted in a host cell.

88. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a Smad polypeptide.

89. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a TGFβ receptor.

90. (Previously presented) The method according to claim 69, wherein the screening assay is conducted *in vitro.*

91. (Previously presented) The method according to claim 69, wherein the screening assay is conducted in a host cell.

92-101 (Canceled)

102. (Previously presented) The method according to claim 69, wherein the screening assay is conducted *in vivo.*

103. (Previously presented) The method according to claim 78, wherein the screening assay is conducted *in vivo.*

104.-106. (Canceled)